FDA approves Eliquis for DVT and PE (VTE) - BMS + Pfizer

BMS and Pfizer Inc. announced the FDA has approved a Supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the reduction in the risk of recurrent DVT and PE following initial therapy. Combined, DVT and PE are known as Venous Thrombo Embolism (VTE). It is estimated that every year, approximately 900,000 Americans are affected by DVT and PE. The FDA approval of Eliquis for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy, is based on data from the global AMPLIFY and AMPLIFY-EXT studies.